Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
In Partnership With:
Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.
The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.
In this episode, Dr Lunning sits down with Neha Mehta-Shah, MD, MSCI, to discuss the current treatment landscape for patients with peripheral T-cell lymphoma (PTCL). Dr Mehta-Shah is an associate professor in the Division of Oncology at Washington University School of Medicine in St. Louis, Missouri.
Drs Lunning and Mehta-Shah highlighted challenges that arise when diagnosing patients with PTCL; how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma; novel frontline agents under investigation in PTCL, and more.
